Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
73.22%
-
Total 13F principal
-
$523,548,048
-
Principal change
-
-$11,741,728
-
Total reported market value
-
$391,837,974
-
Number of holders
-
39
-
Value change
-
-$23,307,900
-
Number of buys
-
19
-
Number of sells
-
13
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q4 2021
As of 31 Dec 2021,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
39 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$523,548,048
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), CITADEL ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, BANK OF AMERICA CORP /DE/, HIGHBRIDGE CAPITAL MANAGEMENT LLC, STATE STREET CORP, Polygon Management Ltd., WELLS FARGO & COMPANY/MN, and MACKAY SHIELDS LLC.
This page lists
40
institutional bondholders reporting positions
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.